drugset / Trial / NCT01510093

Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)

NCT01510093

Phase 2 Completed 10 enrolled Aarhus University Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

This is an exploratory trial with two cross-over arms investigating pharmacokinetic profiles of endogenous and exogenous insulin in type 2 diabetes mellitus patients treated with continuous subcutaneous Insulin Aspart infusion and combined with or without intravenous glucose infusion. The order of treatment session will be randomised. Hypotheses: 1. Secretion of endogenous insulin depends on exogenous insulin supply 2. Secretion of endogenous insulin is depends on plasma glucose levels

Timeline

Start
2012-05
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 0.5 iu Subcutaneous
Subject insulin aspart Protein / enzyme biologic 1.5 iu Subcutaneous